NCT00833027已完成4 期
A 24 Week, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Adding Sitagliptin 100 mg Once Daily in Patients With T2DM Who Have Inadequate Glycemic Control on Metformin Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 608
- 主要终点
- Change From Baseline in HbA1c at Week 24
研究概览
简要总结
Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Sitagliptin
干预措施: sitagliptin phosphate (Drug)
结局指标
主要结局
Change From Baseline in HbA1c at Week 24
时间窗: Baseline and Week 24
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent
次要结局
- Change From Baseline in HbA1c at Week 12(Baseline and Week 12)
研究者
相似试验
已完成
3 期
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)Diabetic Macular EdemaNCT01135914Novartis Pharmaceuticals241
已完成
3 期
Seroquel STACK Study in Schizophrenic or Schizoaffective SubjectsSchizoaffective DisordersSchizophreniaNCT00328978AstraZeneca330
Unknown
不适用
Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)Chronic Hepatitis CNCT03887637Third Affiliated Hospital, Sun Yat-Sen University180
已完成
2 期
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in AdolescentsGastroesophageal Reflux DiseaseNCT01642602Takeda104
已完成
不适用
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent RegimenPsoriasisNCT04149587Bausch Health Americas, Inc.252